cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.24603575.v1
title: Additional file 2 of Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases

description: Additional file 2: Supplemental Table 5. Clinical trials relevant to VCP disease.
DOI: 10.6084/m9.figshare.24603575
title: Additional file 2 of Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases

description: Additional file 2: Supplemental Table 5. Clinical trials relevant to VCP disease.
DOI: 10.6084/m9.figshare.24603647
title: Additional file 2 of Phylogeography and ecological niche modeling implicate multiple microrefugia of Swertia tetraptera during quaternary glaciations

description: Supplementary Material 2
DOI: 10.6084/m9.figshare.24603647.v1
title: Additional file 2 of Phylogeography and ecological niche modeling implicate multiple microrefugia of Swertia tetraptera during quaternary glaciations

description: Supplementary Material 2
DOI: 10.6084/m9.figshare.24603650
title: Additional file 3 of Phylogeography and ecological niche modeling implicate multiple microrefugia of Swertia tetraptera during quaternary glaciations

description: Supplementary Material 3
DOI: 10.6084/m9.figshare.24603650.v1
title: Additional file 3 of Phylogeography and ecological niche modeling implicate multiple microrefugia of Swertia tetraptera during quaternary glaciations

description: Supplementary Material 3
DOI: 10.6084/m9.figshare.24603653
title: Additional file 4 of Phylogeography and ecological niche modeling implicate multiple microrefugia of Swertia tetraptera during quaternary glaciations

description: Supplementary Material 4
DOI: 10.6084/m9.figshare.24603653.v1
title: Additional file 4 of Phylogeography and ecological niche modeling implicate multiple microrefugia of Swertia tetraptera during quaternary glaciations

description: Supplementary Material 4
DOI: 10.6084/m9.figshare.24603920
title: Additional file 3 of A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice

description: Additional file 3. Raw data and statistical analysis results presented in the manuscript.
DOI: 10.6084/m9.figshare.24603920.v1
title: Additional file 3 of A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice

description: Additional file 3. Raw data and statistical analysis results presented in the manuscript.
DOI: 10.6084/m9.figshare.23902848.v1
title: Additional file 2 of Acute coronary syndrome and its treatment outcomes in Ethiopia: a systematic review and meta-analysis

description: Additional file 2: Magnitudes of risk factors among Acute coronary syndrome in Ethiopia.
DOI: 10.6084/m9.figshare.23902848
title: Additional file 2 of Acute coronary syndrome and its treatment outcomes in Ethiopia: a systematic review and meta-analysis

description: Additional file 2: Magnitudes of risk factors among Acute coronary syndrome in Ethiopia.
DOI: 10.26179/tjgq-1x86
title: Tellurometer Readings in Enderby Land, 1976 and 1978
DOI: 10.6084/m9.figshare.24076901.v1
title: Additional file 1 of Structural changes in perineuronal nets and their perforating GABAergic synapses precede motor coordination recovery post stroke

description: Additional file 1. Supplementary ImageJ macros for synapse quantification.
DOI: 10.6084/m9.figshare.24604380
title: Supplementary Material for: Sampling from extracorporeal circuit: a step forward for dose monitoring in CRRT

description: Introduction: Continuous renal replacement therapies (CRRT) require constant monitoring and periodic treatment readjustments, being applied to highly complex patients, with rapidly changing clinical needs. To promote precision medicine in the field of renal replacement therapy and encourage dynamic prescription, the Acute Dialysis Quality Initiative (ADQI) recommends periodically measuring the solutes extracorporeal clearance with the aim of assessing the current treatment delivery and the gap from the therapeutic prescription (often intended as effluent dose). To perform this procedure, it is therefore necessary to obtain blood and effluent samples from the extracorporeal circuit to measure the concentrations of a target solute (usually represented by urea) prefilter, post-filter and in the effluent line. However, samples must be collected simultaneously from the extracorporeal circuit ports, with the same suction flow at unknown rate. Methods: The proposed study takes the first steps toward identifying the technical factors that should be considered in determining the optimal suction rate to collect samples from the extracorporeal circuit to measure the extracorporeal clearance for a specific solute. Results: The results obtained identify the low suction rate (i.e., 1 ml/min) as an ideal parameter for an adequate sampling method. Low velocities do not perturb the external circulation system and ensure stable prevailing pressures in the circuit. Higher velocities can be allowed only with blood flows above 120 ml/min preferably in conditions of appropriate filtration fraction. Discussion/Conclusions: The specific value of aspiration flow rate must be proportioned to the prescription of CRRT treatments set by the clinician.
DOI: 10.6084/m9.figshare.24604389
title: Supplementary Material for: Sampling from extracorporeal circuit: a step forward for dose monitoring in CRRT

description: Introduction: Continuous renal replacement therapies (CRRT) require constant monitoring and periodic treatment readjustments, being applied to highly complex patients, with rapidly changing clinical needs. To promote precision medicine in the field of renal replacement therapy and encourage dynamic prescription, the Acute Dialysis Quality Initiative (ADQI) recommends periodically measuring the solutes extracorporeal clearance with the aim of assessing the current treatment delivery and the gap from the therapeutic prescription (often intended as effluent dose). To perform this procedure, it is therefore necessary to obtain blood and effluent samples from the extracorporeal circuit to measure the concentrations of a target solute (usually represented by urea) prefilter, post-filter and in the effluent line. However, samples must be collected simultaneously from the extracorporeal circuit ports, with the same suction flow at unknown rate. Methods: The proposed study takes the first steps toward identifying the technical factors that should be considered in determining the optimal suction rate to collect samples from the extracorporeal circuit to measure the extracorporeal clearance for a specific solute. Results: The results obtained identify the low suction rate (i.e., 1 ml/min) as an ideal parameter for an adequate sampling method. Low velocities do not perturb the external circulation system and ensure stable prevailing pressures in the circuit. Higher velocities can be allowed only with blood flows above 120 ml/min preferably in conditions of appropriate filtration fraction. Discussion/Conclusions: The specific value of aspiration flow rate must be proportioned to the prescription of CRRT treatments set by the clinician.
DOI: 10.6084/m9.figshare.24604389.v1
title: Supplementary Material for: Sampling from extracorporeal circuit: a step forward for dose monitoring in CRRT

description: Introduction: Continuous renal replacement therapies (CRRT) require constant monitoring and periodic treatment readjustments, being applied to highly complex patients, with rapidly changing clinical needs. To promote precision medicine in the field of renal replacement therapy and encourage dynamic prescription, the Acute Dialysis Quality Initiative (ADQI) recommends periodically measuring the solutes extracorporeal clearance with the aim of assessing the current treatment delivery and the gap from the therapeutic prescription (often intended as effluent dose). To perform this procedure, it is therefore necessary to obtain blood and effluent samples from the extracorporeal circuit to measure the concentrations of a target solute (usually represented by urea) prefilter, post-filter and in the effluent line. However, samples must be collected simultaneously from the extracorporeal circuit ports, with the same suction flow at unknown rate. Methods: The proposed study takes the first steps toward identifying the technical factors that should be considered in determining the optimal suction rate to collect samples from the extracorporeal circuit to measure the extracorporeal clearance for a specific solute. Results: The results obtained identify the low suction rate (i.e., 1 ml/min) as an ideal parameter for an adequate sampling method. Low velocities do not perturb the external circulation system and ensure stable prevailing pressures in the circuit. Higher velocities can be allowed only with blood flows above 120 ml/min preferably in conditions of appropriate filtration fraction. Discussion/Conclusions: The specific value of aspiration flow rate must be proportioned to the prescription of CRRT treatments set by the clinician.
DOI: 10.6084/m9.figshare.24603903
title: Additional file 1 of Causal associations between hand grip strength and pulmonary function: a two-sample Mendelian randomization study

description: Additional file 1: Supplementary Figure S1. Scatter plot of the association of hand grip strength with pulmonary function. Supplementary Figure S2. Forest plot of the association of hand grip strength with pulmonary function. Supplementary Figure S3. Leave-one-out sensitivity analysis of the association of hand grip strength with pulmonary function. Supplementary Figure S4. Funnel plot of the association of hand grip strength with pulmonary function. Supplementary Table S1. Baseline characteristics of hand grip strength and pulmonary function. Supplementary Table S2. Single nucleotide polymorphisms used as instrumental variables in the Mendelian randomization analysis of right-hand grip strength. Supplementary Table S3. Single nucleotide polymorphisms used as instrumental variables in the Mendelian randomization analysis of left-hand grip strength. Supplementary Table S4. SNPs of RHGS excluded from Mendelian randomization analysis. Supplementary Table S5. SNPs of LHGS excluded from Mendelian randomization analysis. STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies.
DOI: 10.6084/m9.figshare.24603903.v1
title: Additional file 1 of Causal associations between hand grip strength and pulmonary function: a two-sample Mendelian randomization study

description: Additional file 1: Supplementary Figure S1. Scatter plot of the association of hand grip strength with pulmonary function. Supplementary Figure S2. Forest plot of the association of hand grip strength with pulmonary function. Supplementary Figure S3. Leave-one-out sensitivity analysis of the association of hand grip strength with pulmonary function. Supplementary Figure S4. Funnel plot of the association of hand grip strength with pulmonary function. Supplementary Table S1. Baseline characteristics of hand grip strength and pulmonary function. Supplementary Table S2. Single nucleotide polymorphisms used as instrumental variables in the Mendelian randomization analysis of right-hand grip strength. Supplementary Table S3. Single nucleotide polymorphisms used as instrumental variables in the Mendelian randomization analysis of left-hand grip strength. Supplementary Table S4. SNPs of RHGS excluded from Mendelian randomization analysis. Supplementary Table S5. SNPs of LHGS excluded from Mendelian randomization analysis. STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies.
DOI: 10.5281/zenodo.8144202
title: Can immature stages be ignored in studies  of forest leaf litter arthropod diversity? A test using Oxford Nanopore DNA barcoding

description: Datasets and results for the study
DOI: 10.5281/zenodo.8144203
title: Can immature stages be ignored in studies  of forest leaf litter arthropod diversity? A test using Oxford Nanopore DNA barcoding

description: Datasets and results for the study
DOI: 10.6084/m9.figshare.24076904.v1
title: Additional file 2 of Structural changes in perineuronal nets and their perforating GABAergic synapses precede motor coordination recovery post stroke

description: Additional file 2. Supplementary MATLAB code for PNN morphology quantification.
DOI: 10.6084/m9.figshare.24076904
title: Additional file 2 of Structural changes in perineuronal nets and their perforating GABAergic synapses precede motor coordination recovery post stroke

description: Additional file 2. Supplementary MATLAB code for PNN morphology quantification.
DOI: 10.6084/m9.figshare.24144019.v1
title: Additional file 6 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 6: Table S3. RNAseq and proteomics differential expression results for RTT - MECP2 versus healthy controls.
DOI: 10.21227/219z-4y29
title: motifMDA

description: To conduct a comprehensive evaluation of MotifMDA's effectiveness, HMDD V2.0 \cite{li2014hmdd} is employed as the benchmark dataset.  It encompasses 495 miRNAs, 383 diseases, and 5,430 human MDAs that have been confirmed through experimental validation. Moreover, another well-regarded database, namely miR2Disease, is also employed as a benchmark dataset in our study. miR2Disease \cite{jiang2009mir2disease} is a comprehensive repository that captures associations between dysfunctional miRNAs and an array of human diseases, and it encompasses 353 miRNAs, 151 diseases, and a total of 2,299 established associations between them. To conduct a comprehensive evaluation of MotifMDA's effectiveness, HMDD V2.0 \cite{li2014hmdd} is employed as the benchmark dataset.  It encompasses 495 miRNAs, 383 diseases, and 5,430 human MDAs that have been confirmed through experimental validation. Moreover, another well-regarded database, namely miR2Disease, is also employed as a benchmark dataset in our study. miR2Disease \cite{jiang2009mir2disease} is a comprehensive repository that captures associations between dysfunctional miRNAs and an array of human diseases, and it encompasses 353 miRNAs, 151 diseases, and a total of 2,299 established associations between them.
DOI: 10.5281/zenodo.10158216
title: Data, codes for the study "Programmable access to microresonator solitons with modulational sideband heating"

description: This archive contains the data for figure 2/3/4, codes for simulation in figure 1 and colds for soliton addressing program in figure 3, in the paper "Programmable access to microresonator solitons with modulational sideband heating".
DOI: 10.5281/zenodo.10158217
title: Data, codes for the study "Programmable access to microresonator solitons with modulational sideband heating"

description: This archive contains the data for figure 2/3/4, codes for simulation in figure 1 and colds for soliton addressing program in figure 3, in the paper "Programmable access to microresonator solitons with modulational sideband heating".
DOI: 10.6084/m9.figshare.24604665
title: Supplementary Material for: Sampling from extracorporeal circuit: a step forward for dose monitoring in CRRT

description: Introduction: Continuous renal replacement therapies (CRRT) require constant monitoring and periodic treatment readjustments, being applied to highly complex patients, with rapidly changing clinical needs. To promote precision medicine in the field of renal replacement therapy and encourage dynamic prescription, the Acute Dialysis Quality Initiative (ADQI) recommends periodically measuring the solutes extracorporeal clearance with the aim of assessing the current treatment delivery and the gap from the therapeutic prescription (often intended as effluent dose). To perform this procedure, it is therefore necessary to obtain blood and effluent samples from the extracorporeal circuit to measure the concentrations of a target solute (usually represented by urea) prefilter, post-filter and in the effluent line. However, samples must be collected simultaneously from the extracorporeal circuit ports, with the same suction flow at unknown rate. Methods: The proposed study takes the first steps toward identifying the technical factors that should be considered in determining the optimal suction rate to collect samples from the extracorporeal circuit to measure the extracorporeal clearance for a specific solute. Results: The results obtained identify the low suction rate (i.e., 1 ml/min) as an ideal parameter for an adequate sampling method. Low velocities do not perturb the external circulation system and ensure stable prevailing pressures in the circuit. Higher velocities can be allowed only with blood flows above 120 ml/min preferably in conditions of appropriate filtration fraction. Discussion/Conclusions: The specific value of aspiration flow rate must be proportioned to the prescription of CRRT treatments set by the clinician.
DOI: 10.6084/m9.figshare.24604665.v1
title: Supplementary Material for: Sampling from extracorporeal circuit: a step forward for dose monitoring in CRRT

description: Introduction: Continuous renal replacement therapies (CRRT) require constant monitoring and periodic treatment readjustments, being applied to highly complex patients, with rapidly changing clinical needs. To promote precision medicine in the field of renal replacement therapy and encourage dynamic prescription, the Acute Dialysis Quality Initiative (ADQI) recommends periodically measuring the solutes extracorporeal clearance with the aim of assessing the current treatment delivery and the gap from the therapeutic prescription (often intended as effluent dose). To perform this procedure, it is therefore necessary to obtain blood and effluent samples from the extracorporeal circuit to measure the concentrations of a target solute (usually represented by urea) prefilter, post-filter and in the effluent line. However, samples must be collected simultaneously from the extracorporeal circuit ports, with the same suction flow at unknown rate. Methods: The proposed study takes the first steps toward identifying the technical factors that should be considered in determining the optimal suction rate to collect samples from the extracorporeal circuit to measure the extracorporeal clearance for a specific solute. Results: The results obtained identify the low suction rate (i.e., 1 ml/min) as an ideal parameter for an adequate sampling method. Low velocities do not perturb the external circulation system and ensure stable prevailing pressures in the circuit. Higher velocities can be allowed only with blood flows above 120 ml/min preferably in conditions of appropriate filtration fraction. Discussion/Conclusions: The specific value of aspiration flow rate must be proportioned to the prescription of CRRT treatments set by the clinician.
DOI: 10.26208/5y4m-0056
title: Colloid milling as an energy efficient cotreatment strategy for lignocellulosic anaerobic digestion

description: Background: In this study, mechanical cotreatment of lignocellulosic biomass with a colloid mill enhanced degradation during anaerobic fermentation. Once-fermented slurry from a mesophilic switchgrass-fed anaerobic digester was subjected to milling (mechanical cotreatment) by recirculating through a colloid mill for various durations (0-min/no-milling, 10-sec/1-pass, 0.5-min/3-passes, 2-min/12-passes, 5-min/30-passes, 10-min/60-passes). Following this, a second fermentation was conducted in batch mode for 19 days.
Results: Biogas production during the fermentation post milling was 82.3±4.1 mL per gram volatile solids for the unmilled control and between 91.3±8 mL g-1 VS (10-sec/1-pass milling) to 102.6±5.2 mL g-1 VS (10-min/60-passes milling) for the milled treatments. Mechanical cotreatment using a colloid mill decreased the mean particle size of the milled treatments relative to the control, and this difference persisted throughout the secondary fermentation post milling. For milling durations up to 0.5 min/3-passes, the bench-scale colloid mill consumed less energy than the additional biogas energy released due to milling.

Conclusions: The results indicate that mechanical cotreatment using a colloid mill can be an efficient strategy for improved biomass solubilization. The Colloid mill also provides additional benefits of being an in-line system that may be implemented at larger scales. Theoretical scale-up calculations based on this finding indicated that the colloid mill may become more energy efficient at larger scales and with higher solids loading rates, thereby making cotreatment an energetically feasible strategy at large scale.
DOI: 10.26179/3nw6-wj58
title: Glaciology 1987 "Traverse 3b" (Law Dome, Wilkes Land) Records and Measurements
DOI: 10.6084/m9.figshare.23937250.v1
title: Additional file 1 of Metastasising ameloblastoma or ameloblastic carcinoma? A case report with mutation analyses

description: Additional file 1.
DOI: 10.6084/m9.figshare.24054451
title: Additional file 3 of A 4-hydroxybenzoate 3-hydroxylase mutant enables 4-amino-3-hydroxybenzoic acid production from glucose in Corynebacterium glutamicum

description: Additional file 3: Nucleotide sequences of the pobA genes codon-optimized for Corynebacterium glutamicum.
DOI: 10.6084/m9.figshare.24054451.v1
title: Additional file 3 of A 4-hydroxybenzoate 3-hydroxylase mutant enables 4-amino-3-hydroxybenzoic acid production from glucose in Corynebacterium glutamicum

description: Additional file 3: Nucleotide sequences of the pobA genes codon-optimized for Corynebacterium glutamicum.
DOI: 10.6084/m9.figshare.24144019
title: Additional file 6 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 6: Table S3. RNAseq and proteomics differential expression results for RTT - MECP2 versus healthy controls.
DOI: 10.6084/m9.figshare.24144013
title: Additional file 4 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 4: Table S1. Detailed description of the study cohort.
DOI: 10.6084/m9.figshare.24144016
title: Additional file 5 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 5: Table S2. Sequence of the designed primers.
DOI: 10.6084/m9.figshare.24144016.v1
title: Additional file 5 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 5: Table S2. Sequence of the designed primers.
DOI: 10.6084/m9.figshare.24144028
title: Additional file 9 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 9: Table S6. Summary for the DEG and DEP from RTT-MECP2 vs MDS and RTT-MECP2 versus RTT-like.
DOI: 10.6084/m9.figshare.24144025.v1
title: Additional file 8 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 8: Table S5. ChEA3 upstream analysis results for RTT patients versus healthy controls, RTT versus MDS, RTT versus RTT-like.
DOI: 10.6084/m9.figshare.24144028.v1
title: Additional file 9 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 9: Table S6. Summary for the DEG and DEP from RTT-MECP2 vs MDS and RTT-MECP2 versus RTT-like.
DOI: 10.6084/m9.figshare.24144025
title: Additional file 8 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 8: Table S5. ChEA3 upstream analysis results for RTT patients versus healthy controls, RTT versus MDS, RTT versus RTT-like.
DOI: 10.6084/m9.figshare.24144022
title: Additional file 7 of Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

description: Additional file 7: Table S4. Enrichment analysis results for the RTT-MECP2 versus healthy controls, RTT versus MDS, RTT versus RTT-like, transcriptomic and proteomic data.